Edward Breitschwerdt, DVM
Chief Scientific Officer
Dr. Breitschwerdt is an internist and professor of medicine and infectious diseases at North Carolina State University’s College of Veterinary Medicine. He is a co-director of the Vector Borne Disease Diagnostic Laboratory, which has been testing animals for vector-borne infections since 1984. Importantly, Dr. Breitschwerdt’s research at the NCSU Intracellular Pathogens Research Laboratory has produced significant research findings concerning the medical importance of Bartonella and other emerging infectious disease pathogens in both animal and human health. With over 300 peer-reviewed publications, Dr. Breitschwerdt is an internationally recognized leader in Bartonella research, diagnosis and treatment and has been consulted widely about an array of infectious diseases by many leading companies in the veterinary diagnostics, therapeutics, and vaccine industries. In recognition of his outstanding contributions to research and teaching, Dr. Breitschwerdt has received numbers awards, including the NCSU Holladay Medal for Excellence (2013), AAVMC Excellence in Research Award (2017), the AKC-CHF Canine Health Excellence Award (2018), the WSAVA Global One Health Award (2018), and the Melanie S. Steele Distinguished Professorship in Medicine (2018).
Amanda B. Elam, PhD
President/Chief Executive Officer
Dr. Elam is President/CEO of Galaxy Diagnostics. She co-founded Galaxy Diagnostics in 2009 and continues to lead corporate strategy and business development activities. Dr. Elam is an entrepreneur and scholar with experience in life sciences and information technology markets. In addition to her leadership role at Galaxy Diagnostics, she holds a Diana Research Fellowship at Babson College where she conducts sponsored research studies for the Center for Women’s Entrepreneurial Leadership (CWEL). Dr. Elam holds a doctorate in Sociology from the University of North Carolina at Chapel Hill and has published extensively on the topic of business start-up and growth in top journals and global research reports. Her doctoral research on entrepreneurship was recognized by the Academy of Management for innovative thought leadership. Galaxy Diagnostics represents Dr. Elam’s first foray into the life sciences industry. As a highly regulated and complex industry, the life sciences provide countless illustrations of the barriers to innovation in healthcare and medicine. The challenges for entrepreneurs and business leaders today include finding better ways to build flexible, efficient organizations and processes to facilitate market innovation.
Ricardo Maggi, PhD
Chief Technical Officer
Dr. Maggi holds a doctorate in molecular biology and is an Associate Professor of Medical Microbiology at the College of Veterinary Medicine at North Carolina State University, where he directs research at the Intracellular Pathogens Research Laboratory. Dr. Maggi brings a diverse background in molecular biology and bacterial culture to Galaxy. He played an integral role in the development of our proprietary diagnostic technology, BAPGM, and leads molecular assay development and bacterial culture for the Galaxy R&D team.
Jennifer Miller, PhD
Director of Research & Development and Lab Operations
Dr. Miller holds a doctorate in microbiology and brings an exceptional and diverse background in microbiology research and education to Galaxy. With over 20 years of experience with vector-borne and zoonotic pathogens, including the Lyme disease spirochete Borrelia burgdorferi, and Leptospira interrogans, the causative agent of leptospirosis, Dr. Miller leads clinical assay development and the diagnostic test portfolio at Galaxy. Her experience as a professor of microbiology at North Carolina State University, where she developed her own research program and laboratory focused on in vitro and murine studies of vector-borne diseases, provides significant insights into optimal research designs and grant proposal strategy in support of Galaxy Contract Research Services.
B. Robert Mozayeni, MD
Dr. Mozayeni is President of ILADS and a board-certified internist in private practice in in Bethesda, Maryland where he specializes in the diagnosis and management of chronic inflammatory diseases having rheumatic and neurovascular manifestations. Dr Mozayeni is a rheumatologist by training with graduate and post-graduate physician-scientist training from Albany Medical College, Yale University, Howard Hughes Medical Institute and the National Institutes of Health (NCI, NHLBI and NIAMS). Under an ongoing research collaboration with Dr. Breitschwerdt, Dr. Mozayeni maintains an observational clinical evaluation of the significance of Bartonella infection in a cohort of several hundred human patients with otherwise unexplained chronic conditions. Clinical correlations between Bartonella species and various conditions are being determined as part of ongoing research that continues to redefine diagnostic and therapeutic options as dictated by clinical experience. As founder and Executive Director of the Translational Medicine Group, Dr. Mozayeni helped develop and commercialize software that supports data-driven methods to accelerate the evaluation and improvement of patient-centered care pathways.
Susan Orton, PhD
Dr Orton is the Manager of the Bioterrorism & Emerging Pathogen (BITEP) Unit at the NC State Laboratory of Public Health (NCSLPH). She brings over 20 years of high complexity laboratory testing experience, including eleven years of experience as a CLIA-qualified High Complexity Laboratory Director. Dr Orton holds a doctorate in immunology and a laboratory director certification from the American College of Microbiology (ACM) Board of Medical Laboratory Immunology.
Director of Finance
Ms. Miller is an experienced finance and operations professional working in the RTP area of North Carolina for over twenty years. Focusing primarily on start-up/early stage life science and technology companies, Ms. Miller’s areas of expertise include accounting, financial planning, cash management, budget development, operational and financial forecasting, process development and implementation, payroll and human resources support. Her accomplishments include co-founding xElle Ventures, the first women only angel network in North Carolina; fractional controller for the RTP/Carolina pod of TechCXO, including preparation of companies for acquisition/mergers; facilitator for the Kauffman Foundations Fast Trac program in RTP and Detroit, MI; fund administrator for The Atlantis Group LLC, a member managed North Carolina angel fund. Ms. Miller graduated with a BA in Accounting from Michigan State University and participated in a working/co-op program with the Oldsmobile division of General Motors.